<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gabay, Cem</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">24-Week Data from the Phase 4 ADACTA Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis trial [ADACTA; NCT01119859], suggest that tocilizumab monotherapy may be more effective than adalimumab monotherapy reducing the signs and symptoms of rheumatoid arthritis.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>